Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


WCM 2017 Highlights: Screening & organization

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma.

This highlight consists of the following parts:

  • Anne Cust, MD – epidemiologist, The University of Sydney, Sydney, Australia: The effect of sun exposure to melanoma
  • Georg Brunner, MD – moleculair-biologist, NeraCare GmbH, Köhln, Germany: Identification of thin fatal melanomas by a gene-signature based risk score
  • Prof. Grant McArthur, MD – oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia: Genetic testing for skin cancer in 2017 and beyond
  • This program is editorially independent and is financially made possible by

Related items

Congress news

WCM 2017 Highlights: Immunotherapy

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma. This highlight consists of the following parts: Prof. Caroline Robert, MD – dermatologist, Institute Gustave-Roussy, Paris, France: The latest results of immunotherapy in melanoma Alain Algazi, MD – oncologist, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA: Clinical immune monitoring and biomarker data of pIL-12 monotherapy compared to pIL-12 with pembrolizumab in metastatic melanoma Sapna Patel, MD – oncologist, MD Anderson Cancer Center, Houston, USA: A phase II study of glembatumumab vedotin for metastatic uveal melanoma

Congress news

WCM 2017 Highlights: Surgery

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma. This highlight consists of the following parts: Jeffrey Gershenwald, MD – surgical-oncologist, MD Anderson Cancer Center, Houston, USA: The new AJCC melanoma classification Prof. John Thompson, MD – surgical-oncologist, The University of Sydney, Sydney, Australia: Surgery for stage IV melanoma patients: is it still worthwhile?

Congress news

WCM 2017 Highlights: Biomarker immunotherapy

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma. This highlight consists of the following parts: Michele Teng, PhD – research scientist, QIMR Berghofer Medical Research Institute, Brisbane, Australia: Why does immunotherapy works so well for melanoma? Prof. Levesque Mitchell, MD – dermatologist, University of Zurich Hospital, Zürich, Switzerland: High dimensional single-cell analysis identifies classical monocyte frequencies to be predictive of PFS to anti-PD-1 immunotherapy Prof. Nikolas Haass, MD – dermatologist, University of Queensland, Brisbane, Australia: Tumor heterogeneity, plasticity and drug resistance

Other

Publication Update on metastatic melanoma

Publication: Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, 15(4), 2014 Author: Dr Christian Blank, medical oncologist, Antoni van Leeuwenhoek Hospital, Amsterdam Article

Other

Publication Update on metastatic melanoma

Publication: Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, 15(4), 2014 Author: Dr Christian Blank, medical oncologist, Antoni van Leeuwenhoek Hospital, Amsterdam Article